drugset
Drugs / XCEL-UMC-BETA
last change Dec 2022 re-read 3 minutes ago

XCEL-UMC-BETA

Cell therapy

Developed for
adult acute respiratory distress syndrome · COVID-19 · spinal cord injury
Investigated by
Blood and Tissue Bank of Catalonia · Hospital de Neurorehabilitació Institut Guttmann · Recerca Clínica S.L. · Syntax for Science, S.L

Trials 2

today NCT04390139 · Ph 1/2 NCT03003364 · Ph 1/2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04390139 May 2020 → Dec 2022 COVID-19, adult acute respiratory distress syndrome Blood and Tissue Bank of Catalonia Completed No outcome recorded
Phase 1/2 NCT03003364 Dec 2016 → Jul 2019 spinal cord injury Blood and Tissue Bank of Catalonia Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as XCEL-UMC-BETA ClinicalTrials.gov intervention name — accepted as the source's own label NCT04390139 ↗
1

NCT03003364 ↗
Modality Cell therapy “Intrathecal allogeneic cell therapy in a blinded syringe” NCT03003364 ↗
Route Intrathecal “intrathecal administration (L3 level)” NCT03003364 ↗